Key Insights

Highlights

Success Rate

87% trial completion (above average)

Published Results

22 trials with published results (10%)

Research Maturity

91 completed trials (41% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

6.3%

14 terminated out of 222 trials

Success Rate

86.7%

+0.2% vs benchmark

Late-Stage Pipeline

14%

30 trials in Phase 3/4

Results Transparency

24%

22 of 91 completed with results

Key Signals

22 with results87% success14 terminated

Data Visualizations

Phase Distribution

175Total
Not Applicable (81)
Early P 1 (4)
P 1 (16)
P 2 (44)
P 3 (12)
P 4 (18)

Trial Status

Completed91
Unknown58
Recruiting23
Not Yet Recruiting17
Terminated14
Active Not Recruiting12

Trial Success Rate

86.7%

Benchmark: 86.5%

Based on 91 completed trials

Clinical Trials (222)

Showing 20 of 20 trials
NCT07533019Phase 2Not Yet RecruitingPrimary

A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo

NCT07532330Not ApplicableActive Not RecruitingPrimary

Tyrosine Vs Tacrolimus With NB-UVB in Vitiligo

NCT06218082Not Yet Recruiting

Vitiligo Registry for Adults and Children in the UK

NCT07519031Phase 1Not Yet RecruitingPrimary

Study of Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in Vitiligo

NCT03036995Phase 2CompletedPrimary

Repigmentation Using Apremilast and Phototherapy In Diffuse VITILIGO

NCT02432534Phase 2CompletedPrimary

Atorvastatin in Active Vitiligo

NCT03941808Not ApplicableCompletedPrimary

Gastroprotected Superoxide Dismutase in Combination With UVB vs Placebo and UVB for Treating Vitiligo.

NCT03661866Active Not Recruiting

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

NCT06068218Not ApplicableCompletedPrimary

Translational Assessment of Vitiligo According to Body Locations

NCT07152626Phase 2Not Yet RecruitingPrimary

Combination Approach With Ritlecitinib and nbUVB Compared to Ritlecitinib Alone for Treating Vitiligo

NCT07472816Phase 4Not Yet RecruitingPrimary

The Value of Adding Mini-oral Pulse Steroid Therapy in Preventing Peri-lesional Halo Post Non-cultured Epidermal Cell Suspension (NCES) in Cases With Stable Segmental and Non-acral Vitiligo.

NCT05342519Phase 2Active Not RecruitingPrimary

Daily Topical Rapamycin for Vitiligo

NCT07352293Phase 4RecruitingPrimary

The Value of Methotrexate in NCES for Stable Vitiligo

NCT07353801Phase 4RecruitingPrimary

Oral Mini Pulse Dexamethasone in Pediatric Vitiligo

NCT07398807Early Phase 1RecruitingPrimary

Effectiveness of Micro-needling With 5 Fluorouracil Versus Potent Topical Steroids in the Treatment of Limited Vitiligo

NCT05544448Not ApplicableCompleted

In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases

NCT06625177Phase 1Active Not RecruitingPrimary

A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo

NCT07368673Phase 4CompletedPrimary

Comparative Effectiveness of Ruxolitinib Monotherapy Versus Its Combination With Tacrolimus and Corticosteroids in the Management of Vitiligo: A Randomized Controlled Trial

NCT04237103Phase 2CompletedPrimary

Combination of Methotrexate and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo

NCT07357870Phase 1RecruitingPrimary

A Proof of Concept, Phase 1 Study of CGB-600 for the Topical Treatment of Non-Segmented Facial Vitiligo

Scroll to load more

Research Network

Activity Timeline